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coronary intervention (PCI) with drug-eluting stent (DES) implantation are unclear.
OBJECTIVES This study sought to characterize the determinants and consequences of PDB after PCI.
METHODS The prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents) study was
used to determine the incidence and predictors of clinically relevant bleeding events occurring within 2 years after
hospital discharge. The effect of PDB on subsequent 2-year all-cause mortality was estimated by time-adjusted Cox
proportional hazards regression.
RESULTS Among 8,582 “all-comers” who underwent successful PCI with DES in the ADAPT-DES study, PDB occurred
in 535 of 8,577 hospital survivors (6.2%) at a median time of 300 days (interquartile range: 130 to 509 days)
post-discharge. Gastrointestinal bleeding (61.7%) was the most frequent source of PDB. Predictors of PDB included
older age, lower baseline hemoglobin, lower platelet reactivity on clopidogrel, and use of chronic oral anticoagulation
therapy. PDB was associated with higher crude rates of all-cause mortality (13.0% vs. 3.2%; p < 0.0001). Following
multivariable adjustment, PDB was strongly associated with 2-year mortality (hazard ratio [HR]: 5.03; p < 0.0001), with
an effect size greater than that of post-discharge myocardial infarction (PDMI) (HR: 1.92; p ¼ 0.009).
CONCLUSIONS After successful PCI with DES in an unrestricted patient population, PDB is not uncommon and has
a strong relationship with subsequent all-cause mortality, greater that that associated with PDMI. Efforts to reduce
PDB may further improve prognosis after successful DES implantation. (Assessment of Dual Antiplatelet Therapy With
Drug-Eluting Stents [ADAPT-DES]; NCT00638794) (J Am Coll Cardiol 2015;66:1036–45) © 2015 by the American
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1037AB BR E V I A T I O N S
AND ACRONYM S
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
MACE = major adverse cardiac
event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PDB = post-discharge bleeding
PDMI = post-discharge
myocardial infarctionT he optimal duration of dual antiplatelettherapy (DAPT) after percutaneous coronaryintervention (PCI) with drug-eluting stents
(DES) remains a matter of active debate (1–3). While
DAPT is effective in preventing stent-related and
non–stent-related adverse ischemic events (4), pro-
longed DAPT use is associated with a substantial
risk of bleeding and possibly increased mortality
(5,6). Periprocedural bleeding after PCI has been
shown to be associated with increased short-term
and long-term morbidity and mortality across the
entire clinical spectrum of patients with coronary ar-
tery disease treated with PCI (7–9).SEE PAGE 1046 PRU = P2Y12 reactivity units
ST = stent thrombosis
TVF = target vessel failure
In contrast, the impact and contribution
of nonperiprocedural bleeding events to late mor-
tality is less certain, especially when compared to
post-discharge ischemic events such as myocardial
infarction (MI) (4,10). Therefore, we sought to
evaluate the incidence, predictors, and impact of
clinically signiﬁcant bleeding occurring after hospi-
tal discharge following successful DES implantation
from the large-scale ADAPT-DES (Assessment of
Dual Antiplatelet Therapy With Drug-Eluting Stents)
study.
METHODS
STUDY POPULATION. The ADAPT-DES study was
a prospective, multicenter registry speciﬁcally
designed to determine the association between pla-
telet reactivity and stent thrombosis (ST) after DES.
The design and major outcomes of the ADAPT-DES
study have been previously described (11). In brief,
an “all-comers” population of 8,582 patients were
prospectively enrolled at 11 sites in U.S. and European
hospitals. All patients successfully treated with
1 or more DES and who were adequately loaded
with aspirin and clopidogrel were eligible forMedicines Company. Dr. Duffy has received speaker honoraria from Volcano
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tion or lesion complexity. The only major
exclusion criteria were the occurrence of a
major complication during the procedure or
before platelet function testing, or if bypass
surgery was planned after PCI. Platelet
reactivity on aspirin and clopidogrel was
assessed after an adequate loading period to
ensure full antiplatelet effect using the Ver-
ifyNow Aspirin, P2Y12, and IIb/IIIa assays
(Accumetrics Inc., San Diego, California) (11).
After PCI, patients were treated with aspirin
indeﬁnitely, and clopidogrel was recom-
mended for at least 1 year. All other treat-
ments were per standard of care. Clinical
follow-up was scheduled at 30 days, 1 year,
and 2 years. An independent clinical events
committee blinded to VerifyNow results adjudicated
all events using original source documents. The
institutional review board at each participating cen-
ter approved the study, and all eligible patients
signed written informed consent prior to enrollment.
For the present study, patients included in the
ADAPT-DES study were compared according to the
occurrence of post-discharge bleeding (PDB) at 2
years.
STUDY OBJECTIVES AND DEFINITIONS. The objec-
tives of the present study were to: 1) determine the
incidence of PDB in patients who were in-hospital
event-free after PCI with DES; 2) identify risk factors
associated with the occurrence of PDB; and 3) eval-
uate the time-dependent, multivariable adjusted
effect of PDB on mortality within 2 years after the
index procedure.
PDB was deﬁned as the occurrence of any of the
following: a Thrombolysis In Myocardial Infarction
(TIMI) major or minor bleed; a Global Use of Strate-
gies to Open Occluded Arteries (GUSTO) severe or
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FIGURE 1 Bleeding Rates After Percutaneous Coronary
Intervention
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Cumulative rates of ﬁrst post-discharge bleeding event increased
over time in all patients; a similar pattern was seen when patients
were stratiﬁed according to requirement for blood transfusion.
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1038Intervention Triage Strategy (ACUITY) major bleed;
or any PDB event requiring medical attention.
According to its timing, PDB was deﬁned as early
(<30 days), late (30 days to <1 year), or very late
(1 to 2 years). The following pre-speciﬁed categories
were used to group the site of bleeding: gastrointes-
tinal, genitourinary, central nervous system, retro-
peritoneal, arterial access-site (nonretroperitoneal),
and other.
Endpoints evaluated in the present study
included all-cause mortality, cardiac mortality, MI,
deﬁnite or probable ST, target vessel failure (TVF),
and major adverse cardiac events (MACE). MI was
deﬁned according to the ACUITY criteria (11,12).
Deﬁnite or probable stent thrombosis was deﬁned
according to the Academic Research Consortium
deﬁnition (13). TVF was deﬁned as the composite of
death, MI, or ischemia-driven target vessel revascu-
larization. MACE was deﬁned as the composite of
cardiac death, MI, or ischemia-driven target lesion
revascularization.
STATISTICAL ANALYSIS. Descriptive statistics are
presented as mean  SD and were compared with
the Student t test; categorical variables are reported
as percentages and were tested with the chi-square
test. Event rates during follow-up were estimated
by Kaplan-Meier methods. Unadjusted hazard ratios
for 2-year outcomes were determined from Cox
proportional hazards models with time-dependent
bleeding as the only covariate. Adjusted hazard ra-
tios were estimated from multivariable Cox models
selected by a stepwise process with entry and exit
thresholds set to 0.1. Both PDB and post-discharge MI
(PDMI) were modeled as time-dependent covariates.
All modeling assumptions were checked and
addressed. The effect size of PDB and PDMI were
directly compared using the Wald test, controlling for
other covariates. Statistical analyses were performed
in SAS version 9.4 (SAS Institute, Cary, North Carolina)
and plots were constructed in R (version 3.1.2) using
ggplot2 (version 1.0.0).RESULTS
INCIDENCE AND SITES OF POST-DISCHARGE BLEEDING.
Among the 8,582 patients enrolled in the ADAPT-
DES study who underwent PCI with DES, 8,577
were discharged alive and included in the current
analysis. Median follow-up was 729 days (inter-
quartile range: 703 to 730 days). During follow-up,
535 patients (6.2%) had a total of 662 PDB events
(Figure 1); 82 patients (15.3%) had multiple bleeding
events. The most common site of PDB wasgastrointestinal (Figure 2). Among those experi-
encing bleeding, 168 (31.4%) required a blood
transfusion for treatment. Median time to ﬁrst PDB
was 300 days (interquartile range: 130 to 509 days).
Risk of bleeding accrued constantly over time, and
the rates of ﬁrst bleeding at 30 days, 1 year, and
2 years were 0.7%, 3.8%, and 8.8%, respectively.
The proportions of ﬁrst PDB events in the early
(<30 days), late (30 days to 1 year), and very late
(>1 year) period were 10.5%, 48.2%, and 41.3%,
respectively.
PREDICTORS OF BLEEDING. Per baseline clinical
characteristics (Table 1), patients who had PDB within
2 years were older and more commonly female, and
had a higher proportion of hypertension, hyperlipid-
emia, peripheral arterial disease, congestive heart
failure, previous MI, and previous coronary revascu-
larization. Patients who experienced PDB also had
lower levels of baseline hemoglobin and creatinine
clearance.
When comparing procedural characteristics (Table 1),
patients with PDB were more likely to have multi-
vessel and left main coronary artery disease and more
frequent treatment of calciﬁed and bifurcation lesions
than those in the no-PDB group. Patients with PDB
had a greater number of lesions treated, longer le-
sions, and longer stents. There were no signiﬁcant
differences in median [Q1 to Q3] baseline P2Y12 reac-
tivity units (PRU) on clopidogrel (PDB 188 [97 to 264]
vs. 188 [114 to 260]; p ¼ 0.83) or aspirin reactivity units
(400 [387 to 432] vs. 400 [388 to 424]; p ¼ 0.79) be-
tween the PDB and no-PDB groups, respectively.
Baseline characteristics in patients with PDB
according to the need for blood transfusion are
FIGURE 2 Site of Post-Discharge Bleeding
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Among 444 patients with bleeding and speciﬁed source, gastrointestinal bleeding was the
most predominant cause of post-discharge bleeding. CNS ¼ central nervous system.
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1039reported in Online Table 1. Patients with PDB and
blood transfusions were more commonly female,
had lower baseline hemoglobin levels, and had a
higher proportion of chronic kidney disease at base-
line compared to patients with PDB not requiring
transfusions.
In reviewing medications used in patients with
and without PDB (Online Table 2), patients with PDB
were more commonly treated with oral anti-
coagulation with warfarin and proton pump in-
hibitors, and less commonly on DAPT during the
entire study period. Speciﬁcally, patients experi-
encing PDB had higher rates of DAPT disruption
because of bleeding (29.0% vs. 1.6%; p < 0.0001).
Also, statin use during 2-year follow-up was lower in
patients with PDB, but there were no differences in
nonsteroidal anti-inﬂammatory drug use between
groups.
The multivariable adjusted independent predictors
of PDB within 2-year follow-up were older age, pe-
ripheral artery disease, lower baseline hemoglobin
levels, lower baseline PRU, and warfarin use at
discharge. Treatment of heavily calciﬁed lesions and
bifurcations were also independent predictors of PDB
(Table 2).
2-YEAR CLINICAL OUTCOMES AND PREDICTORS OF
ALL-CAUSE MORTALITY. Unadjusted 2-year clinical
outcomes according to the occurrence of PDB are re-
ported in Table 3. Patients experiencing PDB had
higher crude rates of all-cause mortality (13.0% vs.
3.2%; p < 0.0001) (Figure 3A) as well as higher rates of
cardiac mortality (5.1% vs. 1.9%; p < 0.0001)
(Figure 3A), MI, ST, TVF, and MACE. PDB occurring
between 30 days and 1 year or 1 year and 2 years were
both associated with increased mortality (Figure 3B).
Patients who had PDB and received blood trans-
fusions had the highest rates of 2-year all-cause and
cardiac mortality (Figure 4).
By multivariable analysis, PDB was the strongest
predictor of 2-year mortality (hazard ratio: 5.03; 95%
conﬁdence interval: 3.29 to 7.66; p < 0.0001)
(Table 4). The effect of PDB with or without trans-
fusion on mortality was similar. The magnitude of the
effect of PDB on subsequent mortality was roughly
2.6-fold greater than the effect of PDMI (hazard ratio:
1.92; 95% conﬁdence interval: 1.18 to 3.12; p ¼ 0.009)
(p ¼ 0.008 for the effect size of PDB vs. PDMI).
DISCUSSION
The current report, drawn from 8,577 patients un-
dergoing successful PCI with DES, is the largest
contemporary study to evaluate the incidence, pre-
dictors, and prognostic impact of PDB in an all-comers patient population (Central Illustration). The
main ﬁndings of the present analysis include: 1) PDB
requiring medical attention was not uncommon and
increased monotonically throughout the 2-year post-
PCI follow-up period; 2) clinical and pharmacologic
risk factors, including lower PRU and concomitant
oral anticoagulation use, were strongly associated
with the risk of PDB; and 3) PDB with or without
associated transfusion was strongly associated with
subsequent mortality, with an adjusted hazard
greater than that for PDMI.
In the all-comers ADAPT-DES population, PDB
occurred in approximately 1 of every 15 patients
within 2 years of follow-up, with more than 50% of
PDB events occurring beyond 300 days. In a time-
adjusted multivariable analysis (accounting for the
timing of occurrence of bleeding and MI events),
PDB was not only more frequent than PDMI (662
PDB events compared with 391 PDMI events), but
also was associated with an approximate 2.6-fold
greater risk of subsequent mortality. These data
extend prior reports demonstrating that the risk of
bleeding is at least as prognostically important as
MI (2,4–6,10). The ongoing risk and strong associa-
tion between PDMI and mortality may underlie the
recent ﬁndings from randomized trials that shorter
DAPT duration may result in improved survival
compared to prolonged DAPT, presumably by mini-
mizing bleeding-related complications (3,5,6).
Nonetheless, some patients at high risk for throm-
botic events, such as those with prior MI, might still
beneﬁt from more potent and prolonged DAPT
(2,14). Choosing those patients who may beneﬁt
from shorter versus longer DAPT requires balancing
the risk of future atherothrombotic events and
TABLE 1 Baseline Clinical and Procedural Characteristics
PDB (n ¼ 535)
No PDB
(n ¼ 8,042) p Value
Clinical characteristics
Age, yrs 67.0  10.4 63.4  10.8 <0.0001
Male 373 (69.7) 5,982 (74.4) 0.02
White 489 (91.4) 7,111 (88.4) 0.04
Body mass index, kg/m2 29.0  6.3 29.5  5.7 0.09
Diabetes mellitus 193 (36.1) 2,588 (32.2) 0.06
Hypertension 461 (86.2) 6,368 (79.2) 0.0001
Hyperlipidemia 427 (79.8) 5,949 (74.0) 0.003
Current smoker 111 (20.7) 1,829 (22.7) 0.29
Previous MI 158 (29.5) 2,006 (24.9) 0.02
Previous PCI 267 (49.9) 3,411 (42.4) 0.0007
Previous CABG 113 (21.1) 1,354 (16.8) 0.01
Peripheral arterial disease 92 (17.2) 782 (9.7) <0.0001
Renal insufﬁciency 87 (16.3) 571 (7.1) <0.0001
Dialysis 24 (4.5) 114 (1.4) <0.0001
Congestive heart failure 69 (12.9) 630 (7.8) <0.0001
Ejection fraction, % 55.0  13.71 54.9  12.34 0.91
Ejection fraction <40% 199 (37.2) 2,376 (29.5) 0.0002
Clinical presentation
Stable coronary artery disease 278 (52.0) 3,871 (48.1) 0.09
Acute coronary syndrome 257 (48.0) 4,171 (51.9) 0.08
Unstable angina 147 (27.5) 2,219 (27.6) 0.95
Non–ST-segment elevation MI 80 (15.0) 1,168 (14.5) 0.79
ST-segment elevation MI 30 (5.6) 784 (9.7) 0.002
Hemoglobin, g/dl 13.3  1.6 14.0  1.5 <0.0001
Platelet count, 103/dl 228.7  70.4 226.6  62.5 0.51
White blood cell count, 103/ml 8.30  4.85 7.93  3.05 0.08
Creatinine clearance, ml/min* 83.0  40.0 94.8  37.1 <0.0001
Angiographic and procedural characteristics
Vascular access site
Femoral 508 (95.0) 7,676 (95.4) 0.60
Radial 23 (4.3) 352 (4.4) 0.93
Brachial 4 (0.7) 14 (0.2) 0.02
Number of diseased vessels
1 170 (31.8) 3,112 (38.7) 0.001
2 174 (32.5) 2,659 (33.1) 0.80
3 191 (35.7) 2,271 (28.2) 0.0002
Number of lesions per patient 1.6  0.8 1.5  0.8 0.1
Total lesion length, mm 29.2  21.0 26.9  20.0 0.01
Number of stents per patient 1.8  1.1 1.7  1.0 0.009
Total stent length, mm 35.0  23.4 32.3  22.3 0.006
Pre-procedural TIMI ﬂow 0/1 40 (7.5) 748 (9.3) 0.15
Post-procedural TIMI ﬂow 3 530 (99.1) 7,995 (99.4) 0.40
Thrombus 69 (12.9) 1,213 (15.1) 0.17
Calciﬁed lesion 211 (39.4) 2,433 (30.2) <0.0001
Bifurcation lesion 104 (19.4) 1,222 (15.2) 0.008
Chronic total occlusion 33 (6.2) 372 (4.6) 0.10
Location†
Left anterior descending artery 242/658 (36.8) 3,707/9,450 (39.2) 0.21
Right coronary artery 202/658 (30.7) 2,984/9,450 (31.6) 0.63
Left main coronary artery 36/658 (5.5) 283/ 9,450 (3.0) 0.0004
Intravascular ultrasound use 208 (38.9) 3153 (39.2) 0.89
Values are n (%) or mean  SD. *Calculated by Cockcroft-Gault formula. †Lesion-level analysis, reported as
n/total lesion N (%).
CABG ¼ coronary artery bypass graft; MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention;
TIMI ¼ Thrombolysis In Myocardial Infarction.
TABLE 2 Independent Predictors of PDB Within 2 Years
Variable* HR (95% CI) p Value
Age (per yr increase) 1.02 (1.01–1.03) <0.0001
Warfarin, at discharge 2.31 (1.78–2.99) <0.0001
Peripheral artery disease 1.57 (1.25–1.98) 0.0001
Calciﬁed lesion 1.25 (1.05–1.50) 0.01
Bifurcation lesion 1.32 (1.06–1.64) 0.01
Platelet reactivity units
(per 10-unit decrease)
1.01 (1.01–1.02) 0.002
Baseline hemoglobin
(per g/dl decrease)
1.28 (1.22–1.37) <0.0001
*The candidate covariates considered for inclusion in the model were: in-hospital
bleeding, age, male sex, diabetes, hypertension, hyperlipidemia, congestive heart
failure, peripheral arterial disease, creatinine clearance, pervious percutaneous
coronary intervention, ST-segment elevation MI, baseline hemoglobin, warfarin at
discharge, triple vessel disease, left main disease, coronary calciﬁcation, bifurca-
tion, chronic total occlusion, number of vessels treated, number of lesion treated,
stents implanted, mechanical closure device used, P2Y12 reactivity units, and
aspirin reactivity units.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; PDB ¼
post-discharge bleeding.
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1040bleeding risk. In this regard, some factors associated
with increased risk of bleeding identiﬁed in the
present report also have been associated with future
ischemic events (e.g., advanced age, peripheral
arterial disease, stenting of complex lesions) (15–17).
Other variables, however, are uniquely associated
with greater bleeding risk, such as baseline anemia
and concomitant use of oral anticoagulation.
Considering the individual patient’s thrombotic and
bleeding risk proﬁle to personalize DAPT duration
decisions should improve outcomes after DES im-
plantation, although this decision-making process
will remain challenging in some cases, and must
incorporate patient preferences.
The relationship between PDB and mortality is
likely multifactorial (Central Illustration), including:
1) decrease in circulating blood volume and oxygen-
carrying capacity resulting in hypotension and
propensity to ischemia and arrhythmias; 2) discon-
tinuation of DAPT to manage bleeding, which
compared to DAPT discontinuation for other reasons
has been strongly associated with a higher risk of
thrombotic events, especially when occurring within
the ﬁrst 30 days (18,19); 3) discontinuation of other
life-extending medications to treat hypotension after
bleeding, such as beta-blockers and angiotensin-
converting enzyme inhibitors, which paradoxically
often are not restarted after patient stabilization;
and 4) administration of red blood cell transfusions
and other blood products that have been associated
with systemic vasoconstriction, activation of in-
ﬂammatory pathways, apoptosis, increased platelet
aggregation, and thrombosis (20). An interesting
ﬁnding of the current report is that PDB without
TABLE 3 2-Year Outcomes According to PDB Occurrence
PDB
(n ¼ 535)
No PDB
(n ¼ 8,042)
Unadjusted
HR (95% CI) p Value*
All-cause mortality 13.0 (68) 3.2 (243) 8.14 (5.53–12.00) <0.0001
Cardiac 5.1 (25) 1.9 (144) 4.95 (2.64–9.28) <0.0001
Noncardiac 6.1 (31) 1.2 (87) 10.52 (5.89–18.81) <0.0001
MI 13.5 (68) 4.1 (319) 3.14 (2.02–4.90) <0.0001
Target vessel failure 20.6 (103) 9.0 (685) 2.59 (1.83–3.68) <0.0001
Deﬁnite/probable Stent thrombosis 1.5 (8) 1.0 (81) 3.63 (1.29–10.24) 0.02
MACE† 24.1 (123) 9.9 (758) 2.89 (2.10–3.97) <0.0001
Event rates are Kaplan-Meier estimates reported as % (n). *Wald p value. †Composite of cardiac death, MI, or
target lesion revascularization.
MACE ¼ major adverse cardiac event(s); other abbreviations as in Table 1.
FIGURE 3 All-Cause and Cardiac Mortality According to PDB
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Kaplan-Meier estimates demonstrate higher rates of all-cause mortality (solid line) and
cardiac mortality (dotted line) according to the occurrence of post-discharge bleeding
(PDB) (salmon) compared to no PDB (blue) over 2 years of follow-up (A) as well as the
landmark analysis at 30-day and 1-year follow-up (B).
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1041transfusion was associated with a similar adjusted
hazard for mortality as PDB with transfusion. This
observation may be considered counterintuitive, as
patients receiving transfusions are often sicker,
with multiple comorbidities and greater extent of
bleeding (21). In our study, prior to accounting for
differences in baseline features, PDB with trans-
fusion was associated with greater cardiac and all-
cause mortality than PDB without transfusion.
However, after multivariable adjustment, an inde-
pendent detrimental effect of transfusion was no
longer present in patents with PDB, suggesting that
it is the deleterious effects of bleeding itself
(perhaps in concert with essential medication dis-
continuation) rather than transfusions that may
affect prognosis.
Not surprisingly, concomitant use of oral antico-
agulants (22) and lower levels of PRU on clopi-
dogrel (signifying greater inhibition of adenosine
diphosphate–associated platelet activation) were
strongly associated with development of PDB. This
latter observation suggests a possible role for careful
agent selection and/or dose modiﬁcation of agents
that block the platelet P2Y12 integrin receptor in
patients at high bleeding risk (e.g., the elderly, those
with recent bleeding, or atrial ﬁbrillation requiring
oral anticoagulation). The association between PRU
and late bleeding has been previously demonstrated
(23,24), although no prospective study has yet shown
clinical utility in using PRU to guide treatment de-
cisions. Given the higher rate and prognostic impact
of PDB compared to PDMI, coupled with the im-
proved safety proﬁle of current generation DES
(19,25,26), our study suggests that future in-
vestigations might explore the role of PRU moni-
toring in high bleeding risk patients to ensure that
P2Y12 receptor-mediated platelet inhibition is not
greater than necessary.
Consistent with prior studies (10,27), gastrointes-
tinal bleeding was the most frequent identiﬁable
source of PDB. Interestingly, proton pump inhibitors
were used relatively infrequently at discharge, and at
1 year their use was slightly more common in the
group with PDB, likely a response to the bleed. As
proton pump inhibitors have been shown to signiﬁ-
cantly reduce gastrointestinal bleeding in patients
with selected risk factors (28), more liberal prophy-
lactic use of these agents during DAPT treatment may
improve patient prognosis. Moreover, the predomi-
nance of gastrointestinal bleeding highlights the need
for judicious screening (e.g., careful history, selective
use of gastroscopy and colonoscopy) in appropriate
patients before elective PCI involving DES implanta-
tion requiring prolonged DAPT.Early discontinuation of or removing aspirin
entirely from the DAPT regimen may reduce bleeding
in patients at high risk for hemorrhagic complica-
tions, as suggested in a recent modest-sized trial in
noncomplex post-PCI patients with atrial ﬁbrillation
requiring warfarin anticoagulation (29). This is
consistent with the ADAPT-DES study, which
FIGURE 4 Mortality According to PDB and Need for Transfusion
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Kaplan-Meier estimates of (A) all-cause mortality and (B) cardiac mortality according to
post-discharge bleeding (PDB) occurrence and requirement (or not) of blood transfusion
demonstrate that early after percutaneous coronary intervention, individuals with PDB
needing blood transfusions experience lower or comparable rates of mortality compared to
those with no transfusions, but those rates cross between 9 and 12 months and climb more
sharply thereafter.
TABLE 4 Independent Predictors of All-Cause Mortality at
2 Years
Variable*
Adjusted HR
(95% CI) p Value
PDB† 5.03 (3.29–7.66) <0.0001
With transfusion 4.71 (2.76–8.03) <0.0001
Without transfusion 5.27 (3.32–8.35) <0.0001
Post-discharge MI† 1.92 (1.18–3.12) 0.009
Current smoker 1.69 (1.25–2.29) 0.001
Age (per yr increase) 1.04 (1.02–1.05) <0.0001
Male 1.45 (1.11–1.90) 0.007
Diabetes mellitus 1.48 (1.17–1.88) 0.001
Previous MI 1.42 (1.12–1.81) 0.004
STEMI or non-STEMI presentation 1.41 (1.10–1.83) 0.008
VerifyNow P2Y12 reactivity units >208 1.22 (0.96–1.54) 0.10
IVUS use 0.83 (0.65–1.06) 0.13
Creatinine clearance
(per ml/min increase)‡
0.99 (0.99–1.00) 0.0007
Baseline white blood cells
(per 103/ml increase)
1.03 (1.01–1.04) <0.0001
Baseline hemoglobin (per g/dl increase) 1.18 (1.09–1.28) <0.0001
*The candidate covariates considered for inclusion in the model were: PDB,
post-discharge MI, age, male, diabetes, current smoker, previous MI, baseline
presentation with ST-segment elevation MI (STEMI) or non-STEMI (vs. stable
coronary artery disease), hyperlipidemia, baseline hemoglobin, baseline white
blood cells, baseline platelets, creatinine clearance, VerifyNow P2Y12 reactivity
units >208, and intravascular ultrasound (IVUS) guidance. †Both variables were
included as time-dependent covariates. ‡Calculated by the Cockcroft-Gault
formula.
Abbreviations as in Table 1.
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1042suggested that aspirin resistance was protective from
major bleeding after DES implantation without
affecting MI or stent thrombosis rates (11). However,
given the well-established role of aspirin in secondary
prevention after acute coronary syndrome and in
patients with vascular disease (30), large-scale ran-
domized trials are required before aspirin withdrawal
can be routinely recommended. Several such trials
involving agents such ticagrelor and novel oral anti-
coagulant drugs are ongoing that might provide
insight to this issue (NCT02270242; NCT01813435;
NCT01830543; NCT02164864).STUDY LIMITATIONS. Our study has several strengths
relative to prior similar investigations, including its
large size, prospective nature, recruitment of an all-
comers population (resulting in higher PDB rates
than in previous studies) (4,10), and assessment of
platelet reactivity to aspirin and clopidogrel.
Conversely, our study has several limitations. First,
bleeding events were not independently adjudicated
by a blinded clinical events committee, introducing
potential reporting bias. It is possible that minor
bleeding events were under-reported. Second, the
source of bleeding was not obtained in all patients.
Third, the present study was a post hoc analysis from
the ADAPT-DES study, and as such should be consid-
ered hypothesis generating. Fourth, patients with
major periprocedural complications were excluded
from the ADAPT-DES study, which while representing
a small proportion of contemporary cases, may
represent a high-risk group for subsequent bleeding
and MI. Fifth, prasugrel only became available late
during the ADAPT-DES study recruitment, and tica-
grelor was unavailable; as a result almost all patients
were treated with clopidogrel. Use of novel, more
potent antithrombotic regimens, however, would
have most likely resulted in an increase in PDB and a
decrease in PDMI, further reinforcing our ﬁndings
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Pathophysiological mechanisms linking out-of-hospital clinically signiﬁcant bleeding and mortality after implantation of drug-eluting stents
(DES). Several clinical and pharmacological factors increase the propensity for bleeding under dual antiplatelet therapy (DAPT). Hemorrhagic
events lead to mortality through a direct effect (central pathway) by reducing circulating blood volume as well as reducing blood oxygen-
carrying capacity and tissue hypoxia; and through indirect effect (lateral pathways) by increasing the risk for stent thrombosis (because of
sudden DAPT discontinuation with rebound in platelet reactivity while the DES is still partially endothelialized) as well as cardiac and
noncardiac ischemic events associated with increased thrombogenicity after blood transfusions. Preventing out-of-hospital bleeding after DES
implantation may signiﬁcantly improve survival and long-term prognosis after percutaneous coronary revascularization (PCI).
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1043(31,32). Finally, although we performed a rigorous
multivariable time-adjusted analysis to characterize
the relative risks of PDB and PDMI on subsequent
mortality, the presence of residual confounders
cannot be excluded.
CONCLUSIONS
In an unrestricted PCI population discharged after
successful DES implantation, subsequent bleeding
complications were not uncommon and were strongly
associated with cardiac and all-cause mortality. Themagnitude of the effect of PDB on 2-year mortality
exceeded that of post-discharge MI, underscoring the
frequency and impact of late bleeding events on
prognosis after PCI and the importance of tailoring
antiplatelet approaches in patients undergoing PCI
with DES.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL SKILLS: Because bleeding after hospital
discharge following percutaneous coronary intervention
occurs more frequently and has a greater impact on
mortality than myocardial infarction, physicians should
carefully consider the trade-off between risks of ischemic
and bleeding events to individualize the duration and in-
tensity of antiplatelet therapy.
TRANSLATIONAL OUTLOOK: More research is
needed to develop safer antithrombotic strategies to
reduce the risk of hemorrhagic complications after
deployment of drug-eluting coronary stents, especially in
patients at high risk of bleeding.
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